Abbott: how to get it right in India
This article was originally published in Scrip
There appears to be quite a lot happening at Abbott in India despite the business's somewhat understated style. And if the US company's current strategic intent is anything to go by, we can expect a lot more of Abbott in India and India in Abbott's emerging market thrust going forward.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.